As patients with
non-muscle-invasive bladder cancer (
NMIBC) show a high degree of heterogeneity in
tumor recurrence or progression, many clinicians demand a detailed risk stratification. Although modified
fatty acid metabolism in
cancer cells is reported to reflect malignant phenotypes such as
metastasis, the impact of
fatty acid transporters on
NMIBC has never been investigated. This study examined the clinicopathologic implications of
fatty acid transporters such as
fatty acid transport protein 4 (FATP4), cluster of differentiation 36/
fatty acid translocase (CD36/FAT), and
long chain acyl CoA synthetase 1 (ACSL1) in 286
NMIBC cases. This study revealed that FATP4, CD36, and ACSL1 were overexpressed in 123 (43.0%), 43 (15.0%), and 35 (12.2%)
NMIBC cases, respectively. High FATP4 in
tumor cells was associated with high grade (p = 0.004) and high stage (p = 0.039). High CD36 was related to high grade (p < 0.001), high stage (p = 0.002), and non-papillary growth type (p = 0.004). High ACSL1 showed an association with high grade (p < 0.001), high stage (p = 0.01), non-papillary growth type (p = 0.002), and
metastasis (p = 0.033). High FATP4 was an independent factor predicting short overall survival (OS) (hazard ratio = 3.32; 95% confidence interval, 1.07-10.31; p = 0.038). In conclusion, upregulation of FATP4, CD36, and ACSL1 might promote the
NMIBC progression and could be exploited in clinical risk stratification and targeted
therapy.